• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

根据四种不同测量量表对16例痉挛患者鞘内注射巴氯芬治疗的结果:一项回顾性分析

Results of Intrathecal Baclofen Treatment in Sixteen Spasticity Patients According to Four Different Measurement Scales: A Retrospective Analysis.

作者信息

Gündüz Hasan Burak

机构信息

Neurological Surgery, Bakirkoy Prof. Dr. Mazhar Osman Training and Research Hospital for Psychiatric Neurological Diseases, Istanbul, TUR.

出版信息

Cureus. 2022 Jul 18;14(7):e26980. doi: 10.7759/cureus.26980. eCollection 2022 Jul.

DOI:10.7759/cureus.26980
PMID:35989772
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9385166/
Abstract

Introduction Spasticity is a motor disorder characterized by a velocity-dependent increase in tonic stretch reflexes. It occurs as a result of overstimulation of the stretch reflex and is a component of the upper motor neuron syndrome. Intrathecal Baclofen (ITB) pump administration in patients with a diagnosis of spasticity may be a suitable option for reducing the complaints of the patients and increasing their quality of life. The aim of this study is to analyze clinically and statistically the diagnosis, treatment criteria, and post-treatment results of patients with spasticity who were treated in our clinic. Materials and Method Sixteen patients who were diagnosed with spasticity and placed on an intrathecal Baclofen pump between January 2015 and December 2020 were included in this study. An intrathecal Baclofen trial was first applied to patients who were candidates for the Baclofen pump. The spasticity levels of the patients who decided to have an intrathecal Baclofen pump were scored according to the modified Ashworth scale (MAS) and Penn spasm frequency scale (PSFS). In addition, the scaling of the patients' own conditions according to the visual analogue scale (VAS) and ambulation status according to the modified functional ambulation classification (MFAC) were recorded. All these evaluations were repeated in the preoperative, early postoperative, and follow-up periods. Results The sex distribution of the patients included in the study was equal to eight women and eight men. The age distribution was between 18 and 76. The average age was 40.62 (standard deviation ±17.79). The average preoperative modified Ashworth scale score was 3.73, and the average Penn spasm frequency scale score of the patients was 3.67. The average preoperative modified functional ambulation classification score was 1.87, and the average visual analogue scale score was 6.67. At the end of the second postoperative week, the average modified Ashworth scale score was 1.80 and the average Penn spasm frequency scale score was 1.67. The modified functional ambulation classification score was 2.60 and the visual analogue scale score was 4.58. The average follow-up period of the patients was 64 months. At the end of the follow-up periods, the average late-period modified Ashworth scale score was 1.87, and the Penn spasm frequency scale score was 1.67. The average modified functional ambulation classification score was 3.00, and the average visual analogue scale score was 4.50. Statistically, there was a significant difference between preoperative and postoperative results in both modified Ashworth scale and Penn spasm frequency scale scores (P<0.05). Modified functional ambulation classification preoperative and postoperative comparison results (P<0.05) and visual analogue scale results (P<0.05) were also statistically significant. No significant difference was found between the early postoperative period and the late postoperative period in all measurements (P=1.00). Conclusion Intrathecal Baclofen administration is one of the many treatment options for spasticity. In this way, it has been shown that greater Baclofen efficacy is achieved and its side effects are reduced. It should always be remembered that the process of this treatment is teamwork that requires the participation of more than one specialty branch. Physical therapists, neurologists, pediatricians, and neurosurgeons should be included in this teamwork.

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f9b4/9385166/d883ff68f647/cureus-0014-00000026980-i02.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f9b4/9385166/12df013a02ac/cureus-0014-00000026980-i01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f9b4/9385166/d883ff68f647/cureus-0014-00000026980-i02.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f9b4/9385166/12df013a02ac/cureus-0014-00000026980-i01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f9b4/9385166/d883ff68f647/cureus-0014-00000026980-i02.jpg
摘要

引言

痉挛是一种运动障碍,其特征为紧张性牵张反射随速度增加。它是由于牵张反射过度刺激而发生的,是上运动神经元综合征的一个组成部分。对于诊断为痉挛的患者,鞘内注射巴氯芬(ITB)泵给药可能是减轻患者不适并提高其生活质量的合适选择。本研究的目的是对在我们诊所接受治疗的痉挛患者的诊断、治疗标准和治疗后结果进行临床和统计学分析。

材料与方法

本研究纳入了2015年1月至2020年12月期间诊断为痉挛并接受鞘内巴氯芬泵治疗的16例患者。首先对符合巴氯芬泵治疗条件的患者进行鞘内巴氯芬试验。决定使用鞘内巴氯芬泵的患者的痉挛程度根据改良Ashworth量表(MAS)和宾夕法尼亚痉挛频率量表(PSFS)进行评分。此外,记录患者根据视觉模拟量表(VAS)对自身状况的评分以及根据改良功能步行分类(MFAC)的步行状态。所有这些评估在术前、术后早期和随访期均重复进行。

结果

纳入研究的患者性别分布为8名女性和8名男性。年龄分布在18至76岁之间。平均年龄为40.62岁(标准差±17.79)。术前改良Ashworth量表平均评分为3.73,患者的宾夕法尼亚痉挛频率量表平均评分为3.67。术前改良功能步行分类平均评分为1.87,视觉模拟量表平均评分为6.67。术后第二周结束时,改良Ashworth量表平均评分为1.80,宾夕法尼亚痉挛频率量表平均评分为1.67。改良功能步行分类评分为2.60,视觉模拟量表评分为4.58。患者的平均随访期为64个月。随访期结束时,晚期改良Ashworth量表平均评分为1.87,宾夕法尼亚痉挛频率量表评分为1.67。改良功能步行分类平均评分为3.00,视觉模拟量表平均评分为4.50。统计学上,改良Ashworth量表和宾夕法尼亚痉挛频率量表评分的术前和术后结果之间存在显著差异(P<0.05)。改良功能步行分类术前和术后比较结果(P<0.05)以及视觉模拟量表结果(P<0.05)在统计学上也具有显著意义。所有测量中术后早期和晚期之间未发现显著差异(P = 1.00)。

结论

鞘内注射巴氯芬是痉挛的多种治疗选择之一。通过这种方式,已证明可实现更大的巴氯芬疗效并减少其副作用。应始终牢记,这种治疗过程是一个需要多个专业分支参与的团队合作。物理治疗师、神经科医生、儿科医生和神经外科医生应参与这个团队合作。

相似文献

1
Results of Intrathecal Baclofen Treatment in Sixteen Spasticity Patients According to Four Different Measurement Scales: A Retrospective Analysis.根据四种不同测量量表对16例痉挛患者鞘内注射巴氯芬治疗的结果:一项回顾性分析
Cureus. 2022 Jul 18;14(7):e26980. doi: 10.7759/cureus.26980. eCollection 2022 Jul.
2
Early outcomes after intrathecal baclofen therapy in ambulatory patients with multiple sclerosis.鞘内注射巴氯芬治疗多发性硬化症门诊患者的早期结果。
J Neurosurg. 2018 Oct;129(4):1056-1062. doi: 10.3171/2017.5.JNS162925. Epub 2017 Dec 1.
3
Intrathecal baclofen efficacy for managing motor function and spasticity severity in patients with cerebral palsy: a systematic review and meta-analysis.鞘内注射巴氯芬对脑瘫患者运动功能和痉挛严重程度的管理效果:一项系统评价和荟萃分析。
BMC Neurol. 2024 Apr 27;24(1):143. doi: 10.1186/s12883-024-03647-7.
4
Intrathecal baclofen for spastic hypertonia from stroke.鞘内注射巴氯芬治疗中风引起的痉挛性肌张力亢进
Stroke. 2001 Sep;32(9):2099-109. doi: 10.1161/hs0901.095682.
5
Use of intrathecal baclofen for treatment of severe spasticity in selected patients with motor neuron disease.鞘内注射巴氯芬治疗选择性运动神经元病患者严重痉挛。
Neurorehabil Neural Repair. 2013 Nov-Dec;27(9):828-33. doi: 10.1177/1545968313496325. Epub 2013 Jul 24.
6
Long-term effects of intrathecal baclofen in multiple sclerosis.鞘内注射巴氯芬对多发性硬化症的长期影响。
Clin Neurol Neurosurg. 2016 Apr;143:121-5. doi: 10.1016/j.clineuro.2016.02.016. Epub 2016 Feb 16.
7
Intrathecal baclofen for multiple sclerosis related spasticity: A twenty year experience.鞘内注射巴氯芬治疗多发性硬化相关痉挛:二十年经验。
Mult Scler Relat Disord. 2019 Jan;27:95-100. doi: 10.1016/j.msard.2018.10.009. Epub 2018 Oct 15.
8
Intrathecal and Oral Baclofen Use in Adults With Spinal Cord Injury: A Systematic Review of Efficacy in Spasticity Reduction, Functional Changes, Dosing, and Adverse Events.鞘内注射和口服巴氯芬在脊髓损伤成人患者中的应用:关于降低痉挛、功能变化、剂量及不良事件疗效的系统评价
Arch Phys Med Rehabil. 2023 Jan;104(1):119-131. doi: 10.1016/j.apmr.2022.05.011. Epub 2022 Jun 22.
9
Long-term continuously infused intrathecal baclofen for spastic-dystonic hypertonia in traumatic brain injury: 1-year experience.长期持续鞘内注射巴氯芬治疗创伤性脑损伤所致痉挛性肌张力障碍性高张力:1年经验
Arch Phys Med Rehabil. 1999 Jan;80(1):13-9. doi: 10.1016/s0003-9993(99)90301-5.
10
Functional outcome of intrathecal baclofen administration for severe spasticity.鞘内注射巴氯芬治疗严重痉挛的功能转归
Clin Neurol Neurosurg. 2005 Jun;107(4):289-95. doi: 10.1016/j.clineuro.2004.09.007.

本文引用的文献

1
Intrathecal Baclofen Dosage for Long-Term Treatment of Patients With Spasticity Due to Traumatic Spinal Cord Injuries or Multiple Sclerosis.鞘内注射巴氯芬用于创伤性脊髓损伤或多发性硬化所致痉挛患者的长期治疗。
Ann Rehabil Med. 2019 Oct;43(5):555-561. doi: 10.5535/arm.2019.43.5.555. Epub 2019 Oct 31.
2
How to analyze the Visual Analogue Scale: Myths, truths and clinical relevance.如何分析视觉模拟量表:误区、真相及临床相关性。
Scand J Pain. 2016 Oct;13:67-75. doi: 10.1016/j.sjpain.2016.06.012. Epub 2016 Jul 27.
3
Intrathecal Baclofen therapy in Germany: Proceedings of the IAB-Interdisciplinary Working Group for Movement Disorders Consensus Meeting.
德国鞘内注射巴氯芬疗法:IAB 运动障碍跨学科工作组共识会议纪要
J Neural Transm (Vienna). 2015 Nov;122(11):1573-9. doi: 10.1007/s00702-015-1425-1. Epub 2015 Jul 16.
4
Rate of complications among the recipients of intrathecal baclofen pump in Japan: a multicenter study.日本鞘内注射巴氯芬泵治疗患者的并发症发生率:一项多中心研究。
Neuromodulation. 2013 May-Jun;16(3):266-72; discussion 272. doi: 10.1111/ner.12010. Epub 2012 Dec 14.
5
Intrathecal baclofen pump for spasticity: an evidence-based analysis.鞘内注射巴氯芬泵治疗痉挛:一项基于证据的分析。
Ont Health Technol Assess Ser. 2005;5(7):1-93. Epub 2005 May 1.
6
Complications of intrathecal baclofen pump: prevention and cure.鞘内注射巴氯芬泵的并发症:预防与治疗
ISRN Neurol. 2012;2012:575168. doi: 10.5402/2012/575168. Epub 2012 Mar 24.
7
Clinical assessment and management of spasticity: a review.痉挛的临床评估与管理:综述
Acta Neurol Scand Suppl. 2010(190):62-6. doi: 10.1111/j.1600-0404.2010.01378.x.
8
The incidence and management of tolerance in intrathecal baclofen therapy.鞘内巴氯芬治疗中耐受的发生率和处理。
Spinal Cord. 2009 Oct;47(10):751-6. doi: 10.1038/sc.2009.34. Epub 2009 Mar 31.
9
Intrathecal baclofen management of poststroke spastic hypertonia: implications for function and quality of life.鞘内注射巴氯芬治疗中风后痉挛性肌张力亢进:对功能和生活质量的影响
Arch Phys Med Rehabil. 2006 Nov;87(11):1509-15. doi: 10.1016/j.apmr.2006.08.323.
10
A benefit-risk assessment of baclofen in severe spinal spasticity.巴氯芬用于严重脊髓痉挛的获益-风险评估
Drug Saf. 2004;27(11):799-818. doi: 10.2165/00002018-200427110-00004.